Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

181. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis

Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis Jamula E, Anderson J, Douketis J D CRD summary This review concluded that patients who underwent cataract surgery and who received warfarin therapy were at increased risk of small bleeds that were (...) not clinically significant. This was a well-conducted review and the conclusions are likely to be reliable, but it should be noted that they are based on mostly observational evidence. Authors' objectives To determine the efficacy and safety of continuing warfarin treatment before and after cataract surgery. Searching MEDLINE, EMBASE and CINAHL (from inception to December 2007 or January 2008), The Cochrane library, BIOSIS Previews and C were searched. Search terms were reported. There were no language

DARE.2009

182. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA CRD summary The authors concluded that there was insufficient evidence to support the use of pharmacogenetics to guide warfarin therapy. There were (...) some limitations in the reporting of review methods, but overall the review was well conducted and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the safety and efficacy of genotype-guided warfarin dosing before anticoagulation. Searching PubMed, EMBASE and International Pharmaceutical Abstracts were searched through January 2009. Details of the search strategy were reported as being available online. No language restrictions were applied. Ongoing clinical

DARE.2009

183. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis

Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE CRD summary This generally well-conducted review found no apparent increase in risk of bleeding associated (...) with continued regular doses of warfarin compared to discontinued/modified warfarin doses for patients who underwent minor dental procedures. The conclusions appeared to be supported by the data, but poor quality included studies and risk of language bias suggest the findings should be interpreted with caution. Authors' objectives To determine the effects of continuing warfarin therapy on the risk of bleeding in patients undergoing elective dental surgery. Searching MEDLINE, EMBASE and Cochrane Central

DARE.2009

184. Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis

Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis Cios DA, Baker WL, Sander SD, Phung OJ, Coleman CI CRD summary The authors concluded that patients spent 57% of their time within the therapeutic range while on warfarin (...) treatment. This conclusion was based on heterogeneous studies of unknown quality that may contain publication bias and so cannot be considered reliable. Authors' objectives To evaluate the effect of study level factors on patients treated with warfarin in USA. Searching Studies were included from a previous systematic review (see Other Publications of Related Interest) and MEDLINE, EMBASE, CINAHL, Web of Science and The Cochrane Library were searched from January 2005 to February 2008. Search terms were

DARE.2009

185. Dabigatran versus warfarin in patients with atrial fibrillation.

Dabigatran versus warfarin in patients with atrial fibrillation. 19717844 2009 09 17 2009 09 23 2015 11 19 1533-4406 361 12 2009 Sep 17 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in patients with atrial fibrillation. 1139-51 10.1056/NEJMoa0905561 Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this noninferiority trial (...) , we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran

NEJM2009

186. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. 19966341 2009 12 16 2010 01 05 2015 11 19 1533-4406 361 24 2009 Dec 10 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. 2342-52 10.1056/NEJMoa0906598 The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism (...) . In a randomized, double-blind, noninferiority trial involving patients with acute venous thromboembolism who were initially given parenteral anticoagulation therapy for a median of 9 days (interquartile range, 8 to 11), we compared oral dabigatran, administered at a dose of 150 mg twice daily, with warfarin that was dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The primary outcome was the 6-month incidence of recurrent symptomatic, objectively confirmed venous thromboembolism

NEJM2009

187. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 19683639 2009 08 17 2009 08 27 2015 06 16 1474-547X 374 9689 2009 Aug 15 Lancet (London, England) Lancet Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 534-42 10.1016/S0140-6736(09)61343-X In patients (...) with non-valvular atrial fibrillation, embolic stroke is thought to be associated with left atrial appendage (LAA) thrombi. We assessed the efficacy and safety of percutaneous closure of the LAA for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation. Adult patients with non-valvular atrial fibrillation were eligible for inclusion in this multicentre, randomised non-inferiority trial if they had at least one of the following: previous stroke or transient ischaemic

Lancet2009

188. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. 19217991 2009 02 16 2009 02 27 2016 11 22 1474-547X 373 9663 2009 Feb 14 Lancet (London, England) Lancet Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. 567-74 10.1016/S0140-6736(09)60205-1 The role and dose of anticoagulants in thromboprophylaxis for patients with cancer receiving chemotherapy through central (...) venous catheters (CVCs) is controversial. We therefore assessed whether warfarin reduces catheter-related thrombosis compared with no warfarin and whether the dose of warfarin determines the thromboprophylactic effect. In 68 clinical centres in the UK, we randomly assigned 1590 patients aged at least 16 years with cancer who were receiving chemotherapy through CVCs to no warfarin, fixed-dose warfarin 1 mg per day, or dose-adjusted warfarin per day to maintain an international normalised ratio between

Lancet2009

189. Anticoagulation - warfarin.

Anticoagulation - warfarin. Anticoagulation - warfarin. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006226 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from original guidelines. New on NGC Guideline Summaries NGC:011081 2016 NGC

Singapore Ministry of Health2008

190. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention

Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention 18471451 2008 05 12 2008 06 24 2013 11 21 0002-9149 101 10 2008 May 15 The American journal of cardiology Am. J. Cardiol. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. 1413-7 10.1016/j.amjcard.2008.01.018 The periprocedural management, bleeding risks, and outcomes of patients taking warfarin previous (...) to percutaneous coronary intervention (PCI) have not been well characterized. All patients undergoing PCI in the National Cardiovascular Data Registry from January 1, 2004 to March 31, 2006 were analyzed (n = 307,443). Multivariable modeling was used to evaluate the association between home warfarin use and in-hospital mortality and bleeding (requiring blood transfusion and/or prolonging hospital stay and/or causing hemoglobin drop >3.0 g/dl). Patients undergoing elective PCI and urgent PCI (primary/rescue

EvidenceUpdates2008

191. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy

A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy Article Text Clinical prediction guide A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy Statistics from Altmetric.com No Altmetric

Evidence-Based Medicine (Requires free registration)2008

192. Genetic determinants of response to warfarin during initial anticoagulation.

Genetic determinants of response to warfarin during initial anticoagulation. BACKGROUND: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear. METHODS: In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes (...) (CYP2C9 *1, *2, and *3), VKORC1 haplotypes (designated A and non-A), clinical characteristics, response to therapy (as determined by the international normalized ratio [INR]), and bleeding events. The study outcomes were the time to the first INR within the therapeutic range, the time to the first INR of more than 4, the time above the therapeutic INR range, the INR response over time, and the warfarin dose requirement. RESULTS: As compared with patients with the non-A/non-A haplotype, patients

NEJM2008 Full Text: Link to full Text with Trip Pro

193. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis

Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Andersen L V, Vestergaard P, Deichgraeber P, Lindholt J S, Mortensen L S, Frost L CRD summary This review concluded that warfarin reduced the risk (...) of stroke and systemic embolism in patients with non-valvular atrial fibrillation, but increased the risk of major bleeding. There were several limitations with the included trials and the reporting in the review, such as no validity assessment and potential bias, so the authors' conclusions should be interpreted with caution. Authors' objectives To assess the efficacy of warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation. Searching MEDLINE, EMBASE

DARE.2008

194. Genetic testing for warfarin therapy initiation

Genetic testing for warfarin therapy initiation Genetic testing for warfarin therapy initiation Genetic testing for warfarin therapy initiation Hynicka L M, Cahoon W D, Bukaveckas B L CRD summary This review concluded that the routine use of pharmacogenomic testing for the initiation of warfarin therapy was not supported by the evidence. Given the lack of reporting of the review process and quality assessment, the small number of participants and the likelihood that the review did not include (...) the entire evidence base, the reliability of the conclusions are uncertain. Authors' objectives To evaluate the efficacy of genetic testing for determining the appropriate initial dose of warfarin and the effect of testing on the safety and efficacy of therapy. Searching MEDLINE (1966 to May 2008) and The Cochrane Library (1993 to May 2008) were searched for English-language publications; search terms were reported. Bibliographies of included studies were also scanned. Study selection Studies

DARE.2008

195. Interactions between warfarin and three commonly prescribed fluoroquinolones

Interactions between warfarin and three commonly prescribed fluoroquinolones Interactions between warfarin and three commonly prescribed fluoroquinolones Interactions between warfarin and three commonly prescribed fluoroquinolones Carroll D N, Carroll D G CRD summary This review evaluated a potential increased anticoagulant response during concomitant therapy of warfarin and three commonly prescribed fluoroquinolones. Due to inconsistent findings, the authors concluded (...) that there was insufficient evidence to support a potential increased anticoagulant response. The authors' conclusions were appropriate, but should be considered in the context of the review's methodological weaknesses. Authors' objectives To critically assess a potential increased anticoagulant response during concomitant therapy of warfarin and any of the three commonly prescribed fluoroquinolone antibiotics. Searching MEDLINE/PubMed and International Pharmaceutical Abstracts were searched from inception to January

DARE.2008

196. Does warfarin safely prevent clotting of hemodialysis catheters: a review of efficacy and safety

Does warfarin safely prevent clotting of hemodialysis catheters: a review of efficacy and safety Does warfarin safely prevent clotting of hemodialysis catheters: a review of efficacy and safety Does warfarin safely prevent clotting of hemodialysis catheters: a review of efficacy and safety Willms L, Vercaigne L M CRD summary The authors concluded that there is insufficient evidence to recommend the routine administration of warfarin for preventing thrombosis in tunneled cuffed catheters (...) in haemodialysis patients. The authors’ conclusions appear to reflect the limited evidence presented. However, poor reporting of the review methods make it difficult to comment on the strength of the evidence underlying these conclusions. Authors' objectives To evaluate the efficacy and safety of warfarin used to prevent thrombosis in tunneled cuffed catheters (TCC) in patients undergoing haemodialysis. Searching PubMed, EMBASE, the Cochrane Library and Google Scholar were searched to April 2007; the search

DARE.2008

197. Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy

Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy Article Text Therapeutics Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy Statistics

Evidence-Based Medicine (Requires free registration)2008

198. The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin

The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin Article Text Clinical prediction guide The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2007

199. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) with [mechanical prosthetic mitral valve] receiving long-term [warfarin therapy] what is the [optimal therapeutic INR target]? Clinical Scenario You have inserted a mechanical prosthetic mitral heart valve into a 60-year-old man. He subsequently has a GI bleed while on warfarin so you decide to review the literature to confirm optimal therapeutic INR which minimises long-term thromboembolic and haemorrhagic complications. Search Strategy Medline 1966 to 2006 November Week 3 using OVID interface. EMBASE 1980

BestBETS2007

200. Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes

Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes Article Text Therapeutics Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding

Evidence-Based Medicine (Requires free registration)2007